American Society of Hirudotherapy

Cardiopulmonary bypass in humans: bypassing unfractionated heparin.

Review published in The Annals of thoracic surgery (2000)

Last Updated: June 18, 2026Reviewed by: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Narrative reviewClinical TrialsDrug DevelopmentFrederiksen · The Annals of thoracic surgery, 2000

Abstract

Seven anticoagulants besides unfractionated heparin have been used for human cardiopulmonary bypass (CPB), mainly in patients with heparin-induced thrombocytopenia. The collective experience with these alternative anticoagulants provides a perspective on current efforts aimed at improving CPB anticoagulation. Unfortunately, each alternative currently lacks a standard dosing schedule and a reliable method of monitoring the adequacy of its anticoagulant effect during CPB. Most also lack proven antidotes. Thus, unfractionated heparin remains the anticoagulant of choice for standard CPB.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleReview
Indexed MeSH termsAnticoagulantsCardiopulmonary BypassDose-Response Relationship, DrugDrug Administration ScheduleHeparinHumansThrombocytopenia

Summary

Seven anticoagulants besides unfractionated heparin have been used for human cardiopulmonary bypass (CPB), mainly in patients with heparin-induced thrombocytopenia. The collective experience with these alternative anticoagulants provides a perspective on current efforts aimed at improving CPB anticoagulation.

Why This Matters for Hirudotherapy

This review discusses seven anticoagulants used as alternatives to unfractionated heparin during human cardiopulmonary bypass, primarily in patients with heparin-induced thrombocytopenia. The authors note that each alternative currently lacks a standard dosing schedule, a reliable monitoring method for anticoagulant adequacy during bypass, and, in most cases, a proven antidote, leaving unfractionated heparin as the anticoagulant of choice for standard cardiopulmonary bypass. The abstract does not mention leeches, hirudin, hirudotherapy, or any leech-derived molecules. The article's connection to the American Society of Hirudotherapy is therefore nonexistent based on the abstract alone, as it focuses entirely on conventional anticoagulant alternatives for surgical bypass.

Citation

Cardiopulmonary bypass in humans: bypassing unfractionated heparin.

Frederiksen · The Annals of thoracic surgery, 2000

Added to ASH library: May 28, 2026 · Site last updated: June 18, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.